menu
    • menu
    [{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Royalty Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Daraxonrasib","moa":"RAS(ON)","graph1":"Oncology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":1.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.25,"dosageForm":"Oral Tablet","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Royalty Pharma

    Menu

    Royalty Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Royalty Pharma

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Royalty Pharma

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Revolution Medicines

                            Deal Size : $1,250.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Revolution Medicines Enters into $2 Billion Flexible Funding Agreement with Royalty Pharma

                            Details : The financing aims to advance the development and global commercialization of Revolution's leading RAS(ON) inhibitor portfolio, RMC-6236 (daraxonrasib), is being evaluated for RAS-mutated NSCLC.

                            Product Name : RMC-6236

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 24, 2025

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Revolution Medicines

                            Deal Size : $1,250.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Royalty Pharma

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Royalty Pharma

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zavegepant HCl

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Pfizer Inc

                            Deal Size : $475.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Royalty Pharma Nabs $475M Milestone from Pfizer upon Migraine Nasal Spray

                            Details : Pfizer has given Royalty Pharma an accelerated milestone payment following the US approval of its migraine nasal spray, Zavzpret (zavegepant). Zavzpret was approved by the U.S. FDA, which provides another important new treatment option for migraine patie...

                            Product Name : Zavzpret

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 15, 2023

                            Lead Product(s) : Zavegepant HCl

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Pfizer Inc

                            Deal Size : $475.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth